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In this dose escalation study, 74 adult cancer patients undergoing bone marrow or peripheral blood stem cell
transplantation received fluconazole (400 mg/day) and either normal saline (control) (12 subjects) or micafungin (12.5 to 200 mg/day) (62 subjects) for up to 4 weeks. The maximum tolerated dose (MTD) of micafungin
was not reached, based on the development of Southwest Oncology Group criteria for grade 3 toxicity;
drug-related toxicities were rare. Commonly occurring adverse events considered related to micafungin were
headache (6.8%), arthralgia (6.8%), hypophosphatemia (4.1%), insomnia (4.1%), maculopapular rash (4.1%),
and rash (4.1%). Pharmacokinetic profiles for micafungin on days 1 and 7 were similar. The mean half-life was
approximately 13 h, with little variance after repeated or increasing doses. Mean maximum concentrations of
the drug in serum and areas under the concentration-time curve from 0 to 24 h were approximately proportional to dose. There was no clinical or kinetic evidence of interaction between micafungin and fluconazole. Five
of 12 patients (42%) in the control group and 14 of 62 (23%) in the micafungin-plus-fluconazole groups had a
suspected fungal infection during treatment which resulted in empirical treatment with amphotericin B. The
combination of micafungin and fluconazole was found to be safe in this high-risk patient population. The MTD
of micafungin was not reached even at doses up to 200 mg/day for 4 weeks. The pharmacokinetic profile of
micafungin in adult cancer patients with blood or marrow transplants is consistent with the profile in healthy
volunteers, and the area under the curve is proportional to dose.
Systemic fungal infections contribute to the morbidity and
mortality of immunocompromised patients. The two most
common invasive fungal infections, candidiasis and aspergillosis, are difficult to diagnose in immunocompromised individuals, and treatment of established infections is not always successful. Fluconazole has been shown to have significant activity
against chronic disseminated candidiasis in patients with leukemia, and prophylactic administration of fluconazole to bone
marrow transplant recipients reduces the incidence of systemic
fungal infections. However, in patients at high risk for disseminated Candida infections, suppression of the more common
Candida pathogens may permit some less pathogenic, but intrinsically fluconazole-resistant, Candida species to emerge as
systemic pathogens (1, 6, 15).
Micafungin (FK463; Fujisawa Healthcare, Inc., Deerfield,
Ill.) is an intravenous antifungal agent of the echinocandin
class. A semisynthetic lipopeptide, micafungin possesses potent in vitro and in vivo activities against a broad spectrum of
Candida and Aspergillus species, including activities against
azole-resistant Candida spp. (5, 7, 8, 10, 12). Micafungin acts
by inhibiting the production of 1,3-␤-D-glucan, a key compo-

nent in fungal cell wall synthesis (4). Safety and pharmacokinetic profiles of micafungin have been established for healthy
volunteers following single- and repeated-dose administration
(J. Azuma, I. Yamamoto, M. Ogura, T. Mukai, H. Suematsu,
H. Kageyama, K. Nakahara, Y. Yoshida, and T. Takaya, Abstr.
38th Intersci. Conf. Antimicrob. Agents Chemother., abstr.
F-146, 1998).
The objectives of this study included determining the maximum tolerated dose (MTD) of micafungin and the pharmacokinetic profile of micafungin, with concomitant fluconazole
administration, in adult cancer patients undergoing bone marrow or peripheral stem cell transplantation.

MATERIALS AND METHODS
Study design. This randomized, double-blind, sequential-group, dose escalation, tolerance study was conducted at five centers in the United States between
June 1998 and May 1999. The protocol was approved by the institutional review
board at each study site, and patients gave written informed consent prior to
enrollment. Adult patients were randomized in groups in a ratio of 4:1 at each
dose level to receive fluconazole (400 mg/day) and either micafungin (eight
subjects at each dose level) or normal saline (control; two subjects at each dose
level) for prophylactic antifungal therapy after bone marrow or stem cell transplantation. Micafungin was administered at dosages of 12.5, 25, 50, 75, 100, 150,
and 200 mg/day. The first 10 patients were entered into the study at the lowest
micafungin dose level. Escalation to the next micafungin dose level occurred only
after enrollment was completed at the previous dose level and after at least six
patients randomized to receive micafungin plus fluconazole had completed 7
days of therapy without meeting the criteria for unacceptable toxicity.
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TABLE 1. Patient demographics and baseline characteristics
Value for:
Demographic or baseline characteristic Control patients Micafungin-treated
(n ⫽ 12)
patients (n ⫽ 62)

Gender
No. of females (%)
Race
No. of Caucasians (%)
Age (yr)
Mean ⫾ SD
Range
Mean wt (kg) ⫾ SD
Underlying disease (no. [%])
Hematologic malignancy
Solid tumor
Other
Type of transplantation (no. [%])
Allogeneic
Autologous
Type of cells (no. [%])
Bone marrow cells
Peripheral stem cells
Cord blood cells

7 (58.3)

42 (67.7)

12 (100.0)

50 (80.6)

43.5 ⫾ 11.63
20–56
72.2 ⫾ 13.95

41.9 ⫾ 11.32
19–65
82.6 ⫾ 19.35

7 (58.3)
4 (33.3)
1 (8.3)

35 (56.5)
24 (38.7)
3 (4.8)

6 (50.0)
6 (50.0)

26 (41.9)
36 (58.1)

3 (25.0)
8 (66.7)
1 (8.3)

8 (12.9)
50 (80.6)
4 (6.5)

were excluded. Because the trial was primarily designed to be a safety and
pharmacokinetics study, no primary efficacy endpoint was established. Efficacy
parameters evaluated included incidence of treatment-emergent fungal infections during treatment and posttreatment and a requirement for empirical antifungal therapy.
Statistical methods. At each dose level, the incidence rates of treatmentemergent adverse events, serious adverse events, and those events related to the
study drug (micafungin plus fluconazole or saline plus fluconazole) were summarized. The incidence rates were estimated for systemic fungal infections at the
end of therapy, the proportion of patients with systemic fungal infections during
the posttreatment period, and the proportion of patients requiring additional
systemic antifungal therapy during the posttreatment period.
The pharmacokinetic profiles for micafungin and fluconazole were computed
from the drug concentration-time data by noncompartmental methods (2) with a
reduced data set in which outlier concentrations were removed. The peak drug
concentration in serum (Cmax) and the time of peak drug concentration (Tmax)
were obtained directly from the observed data. The terminal elimination rate
constant (kel) was obtained from a log linear regression of the plasma drug
concentration-time data in the terminal postdistribution phase. The elimination
half-life (t1/2) was calculated with the formula 0.693/kel. The area under the
plasma drug concentration-time curve from 0 to 24 h (AUC0–24) and the area
under the moment curve from 0 to 24 h (AUMC0–24) were calculated by the
log-linear trapezoidal rule. The AUC from 0 h to infinity (AUC0-⬁) was obtained
from the equation AUC0–24 ⫹ Ct/kel, where Ct was the last measurable concentration. The total body clearance (CL) for micafungin on days 1 and 7 was
obtained from the dose divided by the AUC0-⬁ and from the dose divided by the
AUC0–24, respectively (presumed steady state, where 24 h was the dosing interval). The volume of distribution (V) for micafungin was calculated as CL/kel. The
steady-state volume of distribution (Vss) was calculated from the product of CL
and the mean residence time. The mean residence time was obtained with the
equation (AUMC0-⬁/AUC0-⬁) ⫻ T/2, where AUMC0-⬁ was extrapolated with the
equation [(Ct ⫻ t)/kel ⫹ Ct/kel2], where T was the infusion time. The apparent
clearance (CL/F, where F is the bioavailability) for fluconazole on day 7 was
obtained from the dose divided by the AUC0-24 (presumed steady state, where 24
is the dosing interval in hours). The apparent V for fluconazole was calculated as
(CL/F)/kel.
Prior to the analysis, drug concentration data and case report forms were
reviewed for outliers or documentation about errors in the timing of blood
samples or drug infusion and for the contamination of blood samples. Based on
this review, mistiming was found and selected drug concentration values were
excluded for five patients. The second step was to apply a method described by
Tukey (13). Tukey defined “outer fences” as values that are three times the
interquartile range above the upper (75th percentile) quartile and three times
the interquartile range below the lowest (25th percentile) quartile. This proce-
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Patient selection. Male and female patients, 18 to 55 years of age, who underwent a bone marrow or peripheral stem cell transplant were eligible for the
study. Patients were excluded if they had abnormal liver test parameters (aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, or
alkaline phosphatase greater than 2.5 times the upper limit of normal [ULN]),
serum creatinine greater than 2.0 mg/day, clinical or other evidence of a deep or
disseminated fungal infection, a requirement for systemic antifungal agents other
than fluconazole, or a history of anaphylaxis attributed to azole compounds or
echinocandins. Pregnant and nursing women were also excluded.
Procedures. Patients underwent physical examination, clinical assessments of
fungal infection, and blood collection for determination of baseline clinical
laboratory profiles. Patients were evaluated for fungal infections once a week
during treatment, within 48 h after the last treatment, and at 1 and 4 weeks
posttreatment. Blood was collected for hematology and serum chemistry profile
on days 3, 5, and 7 and then twice weekly for the duration of treatment and at 1
and 4 weeks posttreatment. The absolute neutrophil count (ANC) was measured
daily during therapy. Vital signs were measured before and after treatment for
the first 5 days of treatment and thereafter as clinically indicated. Treatmentemergent adverse events with onset occurring after the first administration of
micafungin or saline were recorded through 72 h after the last dose.
Safety monitoring. The medical monitor (D.B.) in collaboration with the
investigators reviewed the safety data (adverse events and laboratory parameters) in order to ensure that the maximum tolerated dose criteria had not been
fulfilled before escalation to the next micafungin dosage cohort.
Pharmacokinetic sampling. Blood samples (2 ml) for plasma separation were
collected for determination of pharmacokinetic parameters on days 1 (micafungin only) and 7 (micafungin and fluconazole) of study drug dosing at 0 (predose),
0.5, 1, 1.5, 2, 4, 6, 8, 10, 18, and 24 h after the start of study drug administration.
The 24-h postdose blood sample was drawn prior to the start of the next day’s
dosing. Predose blood samples were also collected on days 3 and 5. Blood
samples were obtained from a port site separate from that used to administer the
study drug.
Assay methodology. Plasma micafungin concentrations were assayed using a
high-performance liquid chromatography (HPLC) method with a fluorescence
detection system. A validated HPLC method for quantitation of micafungin and
two metabolites (M1 and M2) in plasma (data on file) was transferred and
validated by MDS Harris Laboratories, Inc. In brief, plasma samples were separated from whole blood, acidified with phosphoric acid, precipitated with acetonitrile, and centrifuged prior to dilution with buffer and injection into an HPLC
system. Separation of micafungin, M1, and M2 was achieved with a TosoHaas
TSK-GEL ODS80TM column. The analytes were quantified by fluorescence.
Data were collected and integrated on a VG Multichrom data system for VAX/
VMS. The lower limit of quantitation for micafungin was 0.05 g/ml. The interand intra-assay coefficient of variation values were, respectively, ⱕ6.8 and 3.2%
for micafungin, 5.3 and 2.7% for M1, and 6.1 and 3.2% for M2. Finally, all
individual sample concentration data reported for micafungin and metabolites
M1 and M2 were within the statistical performance of the assay.
A validated HPLC method for the quantitation of fluconazole was employed
by MDS Harris Laboratories, Inc. In brief, octadecyl silane solid-phase extraction columns were used to extract fluconazole from plasma samples. Once eluted
from the extraction column, samples were injected into a reverse-phase HPLC
analytical system. The analyte was quantified with UV light. Data were collected
and integrated on a VG Multichrom data system for VAX/VMS.
Treatment. Study drug treatment was initiated between 48 h prior to transplant and 24 h posttransplant. Micafungin and saline were administered as
100-ml intravenous infusions over 1 h in a blind manner. Fluconazole was
administered either orally (when clinically feasible) or intravenously. Patients
were treated until neutrophil recovery (ANC, ⱖ500 cells/mm3) to a maximum of
4 weeks. At the investigator’s discretion, study drugs could be continued for up
to 5 days after neutrophil recovery.
Therapy was discontinued if unacceptable toxicity developed or if the patient
developed an invasive fungal infection, which was considered to be empirically
established if the patient was neutropenic (ANC, ⬍500 cells/mm3), had a persistent or recurrent fever (⬎100°F or ⬎38°C) for which there was no known
etiology, and failed to respond to at least 96 h of adequate broad-spectrum
antibacterial therapy.
Criteria for evaluation. The primary analysis data set included all patients who
received at least one dose of the study drug. Safety parameters included treatment-emergent adverse events, laboratory measurements, and changes in vital
signs. Dose-limiting toxicity was reached if three separate patients at the same
dose level developed the same Southwest Oncology Group (SWOG) grade 3 or
greater toxicity, and that toxicity was considered at least probably related to the
study drug. Hematologic abnormalities related to the chemotherapy regimen
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TABLE 2. Summary of SWOG grade 3 or 4 toxicities at least possibly related to the study drug
Age (yr)

Sexa

Underlying disease

Type of transplant/cells

Micafungin
dose (mg)

Event

Day of
onset

Duration of
dosing (days)

49
37
28
54

F
F
F
F

Breast carcinoma
Breast carcinoma
CMLb
Breast carcinoma

Autologous/peripheral stem cells
Autologous/peripheral stem cells
Allogeneic/cord blood cells
Autologous/peripheral stem cells

50
150
200
200

Atrial fibrillation
Hypokalemia
Pancreatitis
Maculopapular rash

7
3
30
8

6
10
27
10

a
b

phatemia (4.1%), insomnia (4.1%), maculopapular rash
(4.1%), and rash (4.1%). There were no reports of infusionrelated reactions.
No patients died during treatment. Five patients died during
the posttreatment period, namely, one (8.3%) in the control
group and four (6.5%) in the micafungin-fluconazole groups.
None of the deaths were considered related to either study
drug. Adverse events leading to the discontinuation of the
study drug occurred in two micafungin-treated patients. One
patient was discontinued for an episode of atrial fibrillation (50
mg/day), and one was discontinued for kidney failure (12.5
mg/day).
Mean serum creatinine, AST, ALT, and total bilirubin levels
at baseline and at the end of therapy were comparable across
treatment groups (Table 3). One patient each in the control
group, the group receiving 25 mg of micafungin-fluconazole
per day, and the group receiving 150 mg of micafungin-fluconazole per day experienced an increase in ALT of ⱖ2.5 times
the ULN at the end of therapy. One patient each in the 50- and
75-mg/day micafungin-fluconazole groups experienced an increase in total bilirubin of ⱖ2.5 times the ULN at the end of
therapy.
MTD assessment. No dose-limiting toxicities were observed
and the maximum tolerated dose for micafungin, when used in
combination with fluconazole, was not achieved in this study.
Pharmacokinetics. Prior to analysis, a review of the case
report forms disclosed five samples that were seriously mistimed (e.g., the trough sample was drawn after the start of the
next dose). The Tukey procedure identified 37 additional outliers. A total of 42 values were excluded from the analysis,

dure was applied to the set of data for each time point for the patients in each
dose group.

RESULTS
Patients. A total of 79 patients were enrolled in the study,
and 74 patients received at least one dose of study drug; 12
patients in the control group and 62 patients in the micafunginfluconazole groups (8 patients at 12.5 mg/day, 9 patients at 25
mg/day, 9 patients at 50 mg/day, 9 patients at 75 mg/day, 9
patients at 100 mg/day, 10 patients at 150 mg/day, and 8 patients at 200 mg/day). Patient characteristics were comparable
across dose levels and treatment groups (Table 1).
Study drug administration. The mean duration of study
drug administration was 11.2 ⫾ 3.35 days (range, 4 to 18 days)
in the control group and 10.7 ⫾ 4.31 days (range, 1 to 27 days)
in the micafungin-fluconazole groups.
Safety. Four patients in the micafungin treatment groups
developed a toxicity of grade 3 or greater that was regarded by
the investigator as possibly or probably related to study drug
(Table 2). Of these four patients, three received either 150 or
200 mg of micafungin. The criteria for the MTD were not
fulfilled.
All patients experienced one or more adverse events during
the study. There were no clinically significant differences in the
incidences of adverse events between the control group and
the micafungin-fluconazole-treated groups, nor was there any
evidence of an increased incidence of adverse events in patients who received higher doses of micafungin. The most
common events considered at least possibly related to micafungin were headache (6.8%), arthralgia (6.8%), hypophos-

TABLE 3. Mean laboratory values at baseline and end of therapy by treatment group
Mean value (SD) for indicated group
Lab parameter

Visita

Control
(n ⫽ 12)b

12.5 mg
(n ⫽ 8)

25 mg
(n ⫽ 9)

50 mg
(n ⫽ 9)

75 mg
(n ⫽ 9)

100 mg
(n ⫽ 9)

150 mg
(n ⫽ 10)

200 mg
(n ⫽ 8)

0.69 (0.21)
0.68 (0.21)

0.78 (0.51)
0.89 (0.73)

0.68 (0.14)
0.70 (0.25)

0.63 (0.17)
0.79 (0.39)

0.76 (0.35)
0.72 (0.16)

0.66 (0.17)
0.64 (0.13)

0.75 (0.15)
0.74 (0.20)

0.73 (0.44)
0.89 (0.29)

Creatinine (mg/dl)

Baseline
EOT

AST (U/liter)

Baseline
EOT

35.9 (21.4)
15.3 (5.2)

28.0 (13.2)
19.1 (11.0)

27.6 (20.4)
14.9 (5.8)

46.3 (39.1)
18.6 (8.9)

33.9 (33.1)
15.9 (7.2)

43.6 (18.8)
19.4 (7.9)

37.8 (15.7)
28.7 (14.9)

33.0 (24.5)
21.0 (10.2)

ALT (U/liter)

Baseline
EOT

44.1 (27.4)
23.3 (12.7)

31.0 (19.9)
23.9 (11.1)

26.3 (7.2)
24.1 (25.2)

63.1 (52.4)
35.8 (26.2)

46.4 (34.7)
17.6 (8.0)

38.8 (20.8)
30.3 (34.5)

53.4 (28.6)
38.9 (31.8)

44.6 (39.5)
32.4 (28.1)

Total bilirubin (mg/dl)

Baseline
EOT

a
b

EOT, end of therapy.
n, no. of subjects.

0.63 (0.22)
0.70 (0.26)

0.60 (0.29)
0.64 (0.52)

0.71 (0.33)
0.80 (0.38)

0.86 (0.87)
1.63 (1.75)

0.93 0.60
1.02 (0.61)

0.73 (0.28)
0.89 (0.59)

0.84 (0.72)
0.92 (0.33)

0.68 (0.42)
1.16 (0.53)
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TABLE 4. Mean pharmacokinetic parameters for plasma
micafungin concentrations at days 1 and 7 of dosing by dose group
AUC0–24 AUC0–⬁
Daily
No. of Study Cmax
(h 䡠 g/ (h 䡠 g/
dose
patients day (g/ml)
ml)
ml)
(mg)

12.5
25

75
100
150
200

1
7
1
7
1
7
1
7
1
7
1
7
1
7

0.9
1.1
1.6
4.1
3.6
4.4
5.4
8.3
7.1
22.0
11.7
17.6
13.1
22.6

9.0
11.9
16.6
23.8
33.9
44.3
47.0
63.0
59.9
101.6
103.6
166.7
118.1
210.6

11.6
16.7
24.2
34.9
44.6
64.0
64.3
91.1
81.1
126.2
144.6
230.3
164.3
438.0

11.3
11.5
14.6
12.4
12.5
12.2
12.7
13.4
13.0
12.0
13.0
12.9
14.3
20.1

CL
Vss
(liters/h) (liters)

1.09
1.11
1.14
1.05
1.20
1.06
1.26
1.47
1.25
1.08
1.12
0.98
1.28
0.96

17.7
16.4
23.1
16.4
21.7
18.0
21.8
23.7
23.0
17.3
21.0
16.7
25.6
23.4

which represented 3.2% of the total 1,307 samples obtained.
The pharmacokinetic profiles of micafungin obtained on days
1 and 7 for patients who were treated with 12.5, 25, 50, 75, 100,
150, and 200 mg/day were not appreciably different (Table 4).
The AUC0-⬁ on day 1 was compared to the AUC0–24 on day 7
by using a paired t test, and they showed no statistically significant difference. This result indicates that the accumulation of
micafungin concentrations from days 1 to 7 follows linear pharmacokinetics.
Following a 1-h infusion, biexponential decay was evident
(Fig. 1 and 2). The mean terminal elimination half-life was
approximately 13 h and remained consistent following repeated, and increasing, doses of micafungin. On day 1, both
mean Cmaxs and AUC0-⬁ values were approximately proportional to dose (Fig. 3). On day 7, mean Cmax and AUC0–24
estimates were slightly more varied, as was demonstrated for
day 1, but still proportional to dose. There was some intersubject variability in day 7 Cmaxs, which influenced the means for

FIG. 1. Day 1 plasma micafungin concentrations.
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50

8
8
9
8
9
9
9
8
9
8
10
8
8
8

t1/2
(h)

the individual dose groups; however, mean Cmaxs on day 7
were proportional to dose. The mean CL values were slightly
lower on day 7 than on day 1, but the ranges overlapped, indicating that a change in disposition was unlikely. Similar ranges of
mean V values for days 1 and 7 further supported the lack of
any change in the pharmacokinetics over the 7 days of dosing.
Day 7 fluconazole kinetic profiles were obtained for 16 patients who also received a range of micafungin doses from 12.5
to 200 mg. While there was a relatively wide range in the day
7 fluconazole AUC0–24 (range, 191.69 to 469.48 g 䡠 h/ml),
there was no discernible trend for different fluconazole
AUC0–24s with increasing dose of micafungin. The range of
plasma Cmaxs from approximately 11 to 30 g/ml was obtained
at approximately 1 to 8 h after dosing; plasma drug levels then
declined in a monoexponential manner. The terminal t1/2
ranged from 11.0 to 41.5 h. Apparent clearance was in the
range of 0.15 to 0.53 ml/min/kg of body weight, and the apparent volume of distribution was in the range of 0.33 to 0.79
liters/kg across the micafungin dose groups.
Efficacy. Five out of 12 (41.7%) patients in the control group
had a suspected fungal infection that required the initiation of
empirical antifungal therapy at the end of treatment, compared with 14 of 62 (22.6%) patients in the micafungin-fluconazole groups. The numbers of patients who developed a suspected fungal infection that required empirical therapy by
micafungin dose group were 2 of 8 (12.5 mg), 3 of 9 (25 mg),
2 of 9 (50 mg), 2 of 9 (75 mg), 2 of 9 (100 mg), 1 of 10 (150 mg),
and 2 of 8 (200 mg). One micafungin-fluconazole-treated patient (12.5 mg/day) was discontinued due to a suspected fungal
infection during treatment and was diagnosed with a probable
fungal infection (histoplasmosis) based on a bone marrow biopsy on day 20 (posttreatment). The infection was not confirmed by antigen testing, and a subsequent bone marrow biopsy was negative. Two patients, both in the 75-mg/day group,
developed proven fungal infections. One of these developed
pulmonary infiltrates suggestive of a fungal infection and was
initiated on empirical treatment with amphotericin B and itra-
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conazole after 6 days of study drug therapy. On day 18, a
culture from a lung tissue biopsy showed Cunninghamella bertholetia (in vitro studies indicate that micafungin is not active
against Cunninghamella species (9). The second patient had
evidence of intestinal candidiasis on autopsy, which was not
confirmed by microscopic evaluation. Of the micafungin-fluconazole-treated patients who completed therapy with no indication of a fungal infection, none developed an infection
during the 4-week posttreatment period.
DISCUSSION
Systemic fungal infections are a major concern in immunocompromised patients undergoing bone marrow transplanta-

tion. The two most common invasive fungal infections, candidiasis and aspergillosis, are difficult to diagnose, and treatment
of established infections in immunocompromised patients is
not always successful (1, 6). Amphotericin B is not effective in
all patients and is associated with significant side effects. Fluconazole has been successfully used for the prevention of candidiasis in bone marrow transplant patients, but a number of
resistant species have been identified (15).
The present study was designed to determine the MTD of
micafungin in immunocompromised cancer patients. Since micafungin efficacy data for cancer patients were limited at the
time the study was designed, it was considered prudent to
administer micafungin in combination with a standard antifungal agent, fluconazole.

FIG. 3. Proportionality of day 1 AUC00-⬁ (AUCinf) to micafungin dose in adult bone marrow and stem cell transplant patients. For the
regression line, r2 was equal to 0.83.
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FIG. 2. Day 7 plasma micafungin concentrations.
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significant trend in the prevention of invasive aspergillosis (1 of
425 cases in the micafungin group versus 7 of 457 cases in the
fluconazole group [P ⫽ 0.071]) (14).
The results of this study suggest that the combination of
micafungin and fluconazole is safe and effective for the prevention of fungal infections in immunocompromised patients.
Further, this study characterized the dose-proportional pharmacokinetics of micafungin in adult cancer patients at doses up
to 200 mg/day. Additional clinical studies with micafungin in
this high-risk patient population are warranted.
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Based on the results of this study, micafungin, in combination with fluconazole, appears to be safe in adult cancer patients undergoing autologous or allogeneic bone marrow or
peripheral stem cell transplantation. Patients were treated with
up to 200 mg of micafungin per day, and the criteria for the
MTD were not fulfilled, suggesting that the MTD is higher
than 200 mg/day in this patient population. A subsequent
MTD study of adult cancer patients administered micafungin
at doses up to 8 mg/kg/day without identifying the MTD (R.
Powles, B. Sirohi, R. Chopra, N. Russel, and H. G. Prentice,
Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother.,
abstr. 5217, 2001).
The pharmacokinetic profile of micafungin in combination
with fluconazole in adult cancer patients was consistent with
that of healthy adult males when micafungin was administered
alone (J. Azuma, I. Yamamoto, M. Ogura, T. Mukai, H. Suematsu, H. Kageyama, K. Nakahara, Y. Yoshida, and T.
Takaya, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-146, 1998). Importantly, the exposure (AUC)
was proportional to dose. This observation extends beyond the
200-mg/day dose tested in this study. In another study of adult
cancer patients, the AUC was proportional to dose at doses up
to 8 mg/kg/day (R. Powles et al., Abstr. 41st Intersci. Conf.
Antimicrob. Agents Chemother.). Additional analyses of these
data indicate that gender and race have no effect on the kinetics of micafungin in adult cancer patients.
The kinetics of fluconazole at 400 mg/day in this study when
administered concomitantly with a wide range of micafungin
doses were comparable to published data suggesting no interaction between the two drugs (3). A subsequent drug interaction study (unpublished data) evaluated the pharmacokinetics
of micafungin at 150 mg/day and fluconazole at 200 mg/day in
healthy volunteers. Thirty subjects received fluconazole orally
on day 1, followed by a 1-week wash-out (neither study drug
administered). Micafungin was then administered for 15 consecutive days (days 8 to 22), followed by a single dose of
fluconazole on day 22. Fluconazole pharmacokinetic parameters were not affected by micafungin at steady state (the mean
ratio [90% confidence intervals around the ratio of the means]
for days 22 to 1 for Cmax was 98.8% [94.5 to 103.4%] and for
AUC0-72 was 102.3% [98.8 to 105.9%]). Similarly, micafungin
pharmacokinetic parameters were not affected by single-dose
fluconazole (mean ratio [90% confidence interval around the
ratio of means] for days 22 to 1 for Cmax was 101.7% [99.7 to
103.7%] and for AUC0-72 was 101.1% [100.1 to 102.1%]).
While not designed to assess efficacy, this study suggested
that prophylactic administration of micafungin, with or without
fluconazole, may be useful in preventing opportunistic fungal
infections in adult patients undergoing allogeneic or autologous bone marrow or peripheral cell transplantation. Subsequently, a large (882 subjects), randomized, multicenter trial
that compared micafungin at 50 mg/day to fluconazole at 200
mg/day for prophylaxis in patients undergoing a hematopoietic
stem cell transplant was conducted. Micafungin was significantly better in overall treatment success than fluconazole
(80.0% success for micafungin compared to 73.5% success for
fluconazole [P ⫽ 0.03]). Importantly, both drugs prevented the
occurrence of invasive Candida infections (0.4% with micafungin versus 0.2% with fluconazole), and there was a nearly
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